ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology

For years, antibody-drug conjugates (ADCs) have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

At ASCO 2026 in Chicago, Pedro Valencia, vice president of asset strategy leadership for oncology at AbbVie, joined pharmaphorum editor-in-chief Jonah Comstock to discuss how the promise of improved efficacy and reduced toxicity is priming ADCs to challenge one of oncology's longest-standing treatment approaches.

Looking beyond AbbVie's own data, Valencia reflects on the trends defining this year's ASCO meeting and why the convergence of ADCs, immuno-oncology, and novel combination strategies could mark a pivotal moment for cancer treatment.

Watch the full interview to discover how AbbVie is positioning its oncology portfolio for the ADC era of cancer care.